The latest InSilc plenary meeting was held in Erasmus University Medical Center based in Rotterdam, Netherlands on 29th/30th November. ERASMUS MC is affiliated with Erasmus University and home to its faculty of medicine, is the “largest and one of the most authoritative scientific University Medical Centers in Europe.
The plenary meeting was held almost exactly 1 year after the project kick-off meeting, with project partners providing exciting updates on developments within the Tasks.
The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 777119
The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silicoclinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.
The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term.
InSiSt is a multidisciplinary Consortium with complementary expertise and experience to support the value chain that the project envisages to achieve. Interventional cardiologists, technical partners with extensive expertise in the field of computer modelling and simulation: (i) biomedical imaging (USFD, FORTH), (ii) coronary fluid dynamics (ERASMUSMC, USFD, CBSET), mechanical modelling and biomechanics (POLIMI, FORTH, NUIG, USFD, BIOIRC), experts in the field of in vitro mechanical testing (BIOIRC) and animal studies (CBSET), biology experts (CNR, FORTH), CRO with significant experience in providing services for regulatory authorizations and clinical trials for biomedical products (MCR), Cloud experts for platforms development and integration (FEOPS), Stent Biomedical Industry with high expertise in the design, development and manufacture of coronary stents (BSL) will join forces to accomplish the InSiSt objectives and deliver all the intermediate and final project expected outcomes. The InSiSt Consortium includes 12 partners from 8 different EU countries and one US partner (CBSET).